Drug Discovery Chemistry Platform Unit

Unit Leader

Hiroo Koyama

Ph.D.

Hiroo Koyama

Show

Hide

1987
Ph.D., Graduate School of Pharmaceutical Sciences, The University of Tokyo
1987
Postdoctoral Fellow, Department of Chemistry, Massachusetts Institute of Technology, USA
1990
New Lead Research Laboratories, Sankyo, Co. Ltd.
1991
Senior Research Fellow, Department of Medicinal Chemistry, Merck Research Laboratories, USA
2010
Principal Scientist, Chemistry, PTC Therapeutics Inc., USA
2013
Senior Research Scientist, Drug Discovery Chemistry Platform Unit, RIKEN Center for Molecular Imaging Science
2013
Platform Unit Leader, Drug Discovery Chemistry Platform Unit, RIKEN Center for Life Science Technologies
2018
Unit Leader, Drug Discovery Chemistry Platform Unit, RIKEN Center for Sustainable Resource Science (-current)

Contact

hiroo.koyama

Drug Discovery Chemistry Platform Unit,
Drug Discovery Platforms Cooperation Division,
RIKEN Center for Sustainable Resource Science

#628 6F Main Research Building,
2-1 Hirosawa, Wako, Saitama 351-0198 Japan
Access to Wako

Related links

Outline

Drug Discovery Chemistry Platform Unit
The main focus of our unit is to identify small molecule drug candidates suitable for animal safety studies and subsequent human clinical trials. Our dedicated scientists conduct lead compound generation, and multi-dimensional lead compound optimization on potency to target receptor/enzyme, PKPD profiles, and off-target activities through SAR development. By capitalizing on RIKEN's available expertise in X-ray crystal structure analysis, in-silico modeling studies, and HTS, we strive to expedite the drug discovery process by rational drug design. Our current therapeutic targets include rare genetic diseases and hard-to-treat cancers.

Subjects

  1. Small molecule drug discovery through medicinal chemistry
Area of research in small molecule drug discovery